A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Data Collection and Cut-off
2.3. Treatment and Follow-Up
2.4. Statistical Analysis
3. Results
3.1. Patients’ Clinical Characteristics
3.2. The Construction of SIRS and Its Relationship with OS
3.3. The Association between SIRS and the Clinical Characteristics
3.4. SIRS Is an Independent Prognostic Factor for OS
3.5. Construct and Verify a Nomogram Based on SIRS
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.Y.; Lim, J.E.; Jung, H.H.; Cho, S.Y.; Cho, E.Y.; Lee, S.K.; Yu, J.H.; Lee, J.E.; Kim, S.W.; Nam, S.J.; et al. Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. Breast Cancer Res. Treat. 2018, 171, 737–745. [Google Scholar] [CrossRef]
- Masood, S. Prognostic/predictive factors in breast cancer. Clin. Lab. Med. 2005, 25, 809–825. [Google Scholar] [CrossRef] [PubMed]
- Yersal, O.; Barutca, S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J. Clin. Oncol. 2014, 5, 412–424. [Google Scholar] [CrossRef] [PubMed]
- Sparano, J.A.; Gray, R.J.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E., Jr.; Dees, E.C.; Perez, E.A.; Olson, J.A., Jr.; et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N. Engl. J. Med. 2015, 373, 2005–2014. [Google Scholar] [CrossRef] [PubMed]
- Cardoso, F.; van’t Veer, L.J.; Bogaerts, J.; Slaets, L.; Viale, G.; Delaloge, S.; Pierga, J.Y.; Brain, E.; Causeret, S.; DeLorenzi, M.; et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N. Engl. J. Med. 2016, 375, 717–729. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ellis, M.J.; Suman, V.J.; Hoog, J.; Lin, L.; Snider, J.; Prat, A.; Parker, J.S.; Luo, J.; DeSchryver, K.; Allred, D.C.; et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29, 2342–2349. [Google Scholar] [CrossRef] [Green Version]
- Chechlinska, M.; Kowalewska, M.; Nowak, R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat. Rev. Cancer 2010, 10, 2–3. [Google Scholar] [CrossRef]
- Elinav, E.; Nowarski, R.; Thaiss, C.A.; Hu, B.; Jin, C.; Flavell, R.A. Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13, 759–771. [Google Scholar] [CrossRef] [PubMed]
- Coffelt, S.B.; Wellenstein, M.D.; de Visser, K.E. Neutrophils in cancer: Neutral no more. Nat. Rev. Cancer 2016, 16, 431–446. [Google Scholar] [CrossRef] [Green Version]
- Contursi, A.; Grande, R.; Dovizio, M.; Bruno, A.; Fullone, R.; Patrignani, P. Platelets in cancer development and diagnosis. Biochem. Soc. Trans. 2018, 46, 1517–1527. [Google Scholar] [CrossRef] [PubMed]
- Mandaliya, H.; Jones, M.; Oldmeadow, C.; Nordman, I.I. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl. Lung Cancer Res. 2019, 8, 886–894. [Google Scholar] [CrossRef] [PubMed]
- Trinh, H.; Dzul, S.P.; Hyder, J.; Jang, H.; Kim, S.; Flowers, J.; Vaishampayan, N.; Chen, J.; Winer, I.; Miller, S. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clin. Chim. Acta 2020, 510, 711–716. [Google Scholar] [CrossRef] [PubMed]
- Gupta, D.; Lis, C.G. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr. J. 2010, 9, 69. [Google Scholar] [CrossRef] [Green Version]
- Chang, Y.; An, H.; Xu, L.; Zhu, Y.; Yang, Y.; Lin, Z.; Xu, J. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br. J. Cancer 2015, 113, 626–633. [Google Scholar] [CrossRef]
- Chen, L.; Kong, X.; Yan, C.; Fang, Y.; Wang, J. The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. Oncotargets Ther. 2020, 13, 1397–1412. [Google Scholar] [CrossRef] [Green Version]
- Vrieze, S.I. Model selection and psychological theory: A discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol. Methods 2012, 17, 228–243. [Google Scholar] [CrossRef] [Green Version]
- Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [Google Scholar] [CrossRef]
- Diakos, C.I.; Charles, K.A.; McMillan, D.C.; Clarke, S.J. Cancer-related inflammation and treatment effectiveness. Lancet. Oncol. 2014, 15, e493–e503. [Google Scholar] [CrossRef]
- Wellenstein, M.D.; Coffelt, S.B.; Duits, D.E.M.; van Miltenburg, M.H.; Slagter, M.; de Rink, I.; Henneman, L.; Kas, S.M.; Prekovic, S.; Hau, C.S.; et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 2019, 572, 538–542. [Google Scholar] [CrossRef]
- Shinko, D.; Diakos, C.I.; Clarke, S.J.; Charles, K.A. Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. Clin. Pharmacol. Ther. 2017, 102, 599–610. [Google Scholar] [CrossRef]
- Farhood, B.; Najafi, M.; Mortezaee, K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol. 2019, 234, 8509–8521. [Google Scholar] [CrossRef]
- Diaz-Montero, C.M.; Finke, J.; Montero, A.J. Myeloid-derived suppressor cells in cancer: Therapeutic, predictive, and prognostic implications. Semin. Oncol. 2014, 41, 174–184. [Google Scholar] [CrossRef] [Green Version]
- Dupré, A.; Malik, H.Z. Inflammation and cancer: What a surgical oncologist should know. Eur. J. Surg. Oncol. 2018, 44, 566–570. [Google Scholar] [CrossRef]
- Yang, L.; Liu, Q.; Zhang, X.; Liu, X.; Zhou, B.; Chen, J.; Huang, D.; Li, J.; Li, H.; Chen, F.; et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature 2020, 583, 133–138. [Google Scholar] [CrossRef]
- Sun, X.J.; Ai, L.; Feng, Y.C. The Value of ABO Blood Group and Complete Blood Count for the Prognosis Analysis of Gastric Cancer Patients. Oncotargets Ther. 2020, 13, 4627–4633. [Google Scholar] [CrossRef]
- Poorvu, P.D.; Gelber, S.I.; Rosenberg, S.M.; Ruddy, K.J.; Tamimi, R.M.; Collins, L.C.; Peppercorn, J.; Schapira, L.; Borges, V.F.; Come, S.E.; et al. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women with Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. J. Clin. Oncol. 2020, 38, 725–733. [Google Scholar] [CrossRef] [PubMed]
- Nielsen, T.O.; Parker, J.S.; Leung, S.; Voduc, D.; Ebbert, M.; Vickery, T.; Davies, S.R.; Snider, J.; Stijleman, I.J.; Reed, J.; et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16, 5222–5232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wallden, B.; Storhoff, J.; Nielsen, T.; Dowidar, N.; Schaper, C.; Ferree, S.; Liu, S.; Leung, S.; Geiss, G.; Snider, J.; et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genom. 2015, 8, 54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ibraheem, A.; Olopade, O.I.; Huo, D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer 2020, 126, 4013–4022. [Google Scholar] [CrossRef] [PubMed]
- Cho, U.; Park, H.S.; Im, S.Y.; Yoo, C.Y.; Jung, J.H.; Suh, Y.J.; Choi, H.J. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS ONE 2018, 13, e0200936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, Z.Z.; Hua, X.; Song, C.G.; Xia, W.; Bi, X.W.; Yuan, Z.Y.; He, Z.Y.; Huang, J.J. The Prognostic Prediction Value of Systemic Inflammation Score and the Development of a Nomogram for Patients with Surgically Treated Breast Cancer. Front. Oncol. 2020, 10, 563731. [Google Scholar] [CrossRef]
- Zheng, Y.; Wu, C.; Yan, H.; Chen, S. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study. Clin. Chim. Acta 2020, 506, 110–121. [Google Scholar] [CrossRef] [PubMed]
- Corbeau, I.; Jacot, W.; Guiu, S. Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. Cancers 2020, 12, 958. [Google Scholar] [CrossRef]
- Cullinane, C.; Creavin, B.; O’Leary, D.P.; O’Sullivan, M.J.; Kelly, L.; Redmond, H.P.; Corrigan, M.A. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis. Clin. Breast Cancer 2020, 20, e675–e681. [Google Scholar] [CrossRef] [PubMed]
- Jiang, C.; Lu, Y.; Zhang, S.; Huang, Y. Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. BioMed Res. Int. 2020, 2020, 7961568. [Google Scholar] [CrossRef]
- Sugawara, K.; Yagi, K.; Uemura, Y.; Okumura, Y.; Nishida, M.; Aikou, S.; Yamashita, H.; Seto, Y. Associations of Systemic Inflammation and Sarcopenia with Survival of Esophageal Carcinoma Patients. Ann. Thorac. Surg. 2020, 110, 374–382. [Google Scholar] [CrossRef]
- Wang, J.; Hui, Z.; Men, Y.; Kang, J.; Sun, X.; Deng, L.; Zhai, Y.; Wang, W.; Bi, N.; Liang, J.; et al. Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer. Ann. Thorac. Surg. 2019, 108, 1701–1709. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.; Liu, Q.; Zhu, L.; Zhang, Y.; Lu, X.; Wu, Y.; Liu, L. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci. Rep. 2019, 9, 3284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, J.H.; Zhai, E.T.; Yuan, Y.J.; Wu, K.M.; Xu, J.B.; Peng, J.J.; Chen, C.Q.; He, Y.L.; Cai, S.R. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J. Gastroenterol. 2017, 23, 6261–6272. [Google Scholar] [CrossRef]
Variables | Total (n = 1583) | Training Cohort (n = 1187) | Validation Cohort (n = 396) | p-Value | |||
---|---|---|---|---|---|---|---|
NO. | % | NO. | % | NO. | % | ||
Age | 0.621 | ||||||
≤60 | 1347 | 85.1 | 1007 | 84.8 | 340 | 85.9 | |
>60 | 236 | 14.9 | 180 | 15.2 | 56 | 14.1 | |
Multifocality | 0.641 | ||||||
Yes | 39 | 2.5 | 28 | 2.4 | 11 | 2.8 | |
No | 1544 | 97.5 | 1159 | 97.6 | 385 | 97.2 | |
Grade | 0.06 | ||||||
I | 108 | 6.8 | 90 | 7.6 | 18 | 4.5 | |
II | 903 | 57.0 | 681 | 57.4 | 222 | 56.1 | |
III | 572 | 36.1 | 416 | 35.0 | 156 | 39.4 | |
VCE | 0.577 | ||||||
Yes | 558 | 35.2 | 423 | 35.6 | 135 | 34.1 | |
No | 1025 | 64.8 | 764 | 64.4 | 261 | 65.9 | |
T stage | 0.148 | ||||||
T1 | 717 | 45.3 | 545 | 45.9 | 172 | 43.4 | |
T2 | 760 | 48.0 | 572 | 48.2 | 188 | 47.5 | |
T3 | 60 | 3.8 | 41 | 3.5 | 19 | 4.8 | |
T4 | 46 | 2.9 | 29 | 2.4 | 17 | 4.3 | |
N stage | 0.053 | ||||||
N0 | 828 | 52.3 | 616 | 51.9 | 212 | 53.6 | |
N1 | 402 | 25.4 | 303 | 25.5 | 99 | 25.0 | |
N2 | 207 | 13.1 | 168 | 14.2 | 39 | 9.8 | |
N3 | 146 | 9.2 | 100 | 8.4 | 46 | 11.6 | |
IHC subtype | 0.520 | ||||||
Luminal A | 328 | 20.7 | 256 | 21.6 | 72 | 18.2 | |
Luminal B | 883 | 55.8 | 652 | 54.9 | 231 | 58.3 | |
HER2+ | 184 | 11.6 | 138 | 11.6 | 46 | 11.6 | |
TNBC | 188 | 11.9 | 141 | 11.9 | 47 | 11.9 | |
ALB (g/L) | 0.783 | ||||||
<43 | 830 | 52.4 | 620 | 52.2 | 210 | 53.0 | |
≥43 | 753 | 47.6 | 567 | 47.8 | 186 | 47.0 | |
CRP (mg/L) | 0.361 | ||||||
<3.78 | 1361 | 86.0 | 1026 | 86.4 | 335 | 84.6 | |
≥3.78 | 222 | 14.0 | 161 | 13.6 | 61 | 15.4 | |
PMR | 0.704 | ||||||
<518 | 587 | 37.1 | 437 | 36.8 | 150 | 37.9 | |
≥518 | 996 | 62.9 | 750 | 63.2 | 246 | 62.1 | |
NMR | 0.720 | ||||||
<7.0 | 346 | 21.9 | 262 | 22.1 | 84 | 21.2 | |
≥7.0 | 1237 | 78.1 | 925 | 77.9 | 312 | 78.8 | |
PLR | 0.965 | ||||||
<206 | 1424 | 90.0 | 1068 | 90.0 | 356 | 89.9 | |
≥206 | 159 | 10.0 | 119 | 10.0 | 40 | 10.1 | |
NLR | 0.936 | ||||||
<3.36 | 1377 | 87.0 | 1033 | 87.0 | 344 | 86.9 | |
≥3.36 | 206 | 13.0 | 154 | 13.0 | 52 | 13.1 | |
LMR | 0.410 | ||||||
<7.25 | 1401 | 88.5 | 1046 | 88.1 | 355 | 89.6 | |
≥7.25 | 182 | 11.5 | 141 | 11.9 | 41 | 10.4 |
Variables | Total (n = 1187) | SIRS High (n = 482) | SIRS Low (n = 705) | p-Value | |||
---|---|---|---|---|---|---|---|
NO. | % | NO. | % | NO. | % | ||
Age | 0.072 | ||||||
≤60 | 1007 | 84.8 | 398 | 82.6 | 609 | 86.4 | |
>60 | 180 | 15.2 | 84 | 17.4 | 96 | 13.6 | |
Multifocality | 0.004 | ||||||
Yes | 28 | 2.4 | 4 | 0.8 | 24 | 3.4 | |
No | 1159 | 97.6 | 478 | 99.2 | 681 | 96.6 | |
Grade | 0.588 | ||||||
I | 90 | 7.6 | 40 | 8.3 | 50 | 7.1 | |
II | 681 | 57.4 | 269 | 55.8 | 412 | 58.4 | |
III | 416 | 35.0 | 173 | 35.9 | 243 | 34.5 | |
VCE | 0.477 | ||||||
Yes | 423 | 35.6 | 166 | 34.4 | 257 | 36.5 | |
No | 764 | 64.4 | 316 | 65.6 | 448 | 63.5 | |
T stage | 0.187 | ||||||
T1 | 545 | 45.9 | 212 | 44.0 | 333 | 47.2 | |
T2 | 572 | 48.2 | 235 | 48.8 | 337 | 47.8 | |
T3 | 41 | 3.5 | 23 | 4.8 | 18 | 2.6 | |
T4 | 29 | 2.4 | 12 | 2.5 | 17 | 2.4 | |
N stage | 0.017 | ||||||
N0 | 616 | 51.9 | 253 | 52.5 | 363 | 51.5 | |
N1 | 303 | 25.5 | 105 | 21.8 | 198 | 28.1 | |
N2 | 168 | 14.2 | 72 | 14.9 | 96 | 13.6 | |
N3 | 100 | 8.4 | 52 | 10.8 | 48 | 6.8 | |
IHC subtype | 0.096 | ||||||
Luminal A | 256 | 21.6 | 105 | 21.8 | 151 | 21.4 | |
Luminal B | 652 | 54.9 | 271 | 56.2 | 381 | 54.0 | |
HER2+ | 138 | 11.6 | 43 | 8.9 | 95 | 13.5 | |
TNBC | 141 | 11.9 | 63 | 13.1 | 78 | 11.1 |
Variables | Univariate Cox Analysis | Multivariate Cox Analysis | ||
---|---|---|---|---|
HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
Age | 0.003 | 0.014 | ||
≤60 | Reference | Reference | ||
>60 | 1.965(1.267–3.046) | 1.778(1.124–2.814) | ||
SIRS | <0.001 | <0.001 | ||
Low | Reference | Reference | ||
High | 1.543(1.266–1.879) | 2.399(1.607–3.583) | ||
Multifocality | 0.340 | |||
No | Reference | |||
Yes | 0.383(0.053–2.747) | |||
Grade | 0.027 | 0.433 | ||
I | Reference | Reference | ||
II | 0.906(0.410–2.000) | 0.807 | 0.591(0.259–1.351) | 0.213 |
III | 1.553(0.703–3.433) | 0.276 | 0.678(0.294–1.566) | 0.363 |
VCE | <0.001 | 0.039 | ||
No | Reference | Reference | ||
Yes | 2.426(1.647–3.573) | 1.566(1.022–2.398) | ||
T stage | <0.001 | 0.021 | ||
T1 | Reference | Reference | ||
T2 | 1.995(1.279–3.112) | 0.002 | 1.395(0.879–2.211) | 0.158 |
T3 | 4.538(2.147–9.588) | <0.001 | 2.210(0.992–4.924) | 0.052 |
T4 | 4.947(2.166–11.298) | <0.001 | 3.428(1.455–8.076) | 0.005 |
N stage | <0.001 | <0.001 | ||
N0 | Reference | Reference | ||
N1 | 1.887(1.111–3.204) | 0.019 | 2.074(1.194–3.603) | 0.010 |
N2 | 2.560(1.436–4.566) | 0.001 | 2.137(1.138–4.014) | 0.018 |
N3 | 8.140(4.883–13.572) | <0.001 | 5.876(3.341–10.334) | <0.001 |
IHC subtype | <0.001 | 0.001 | ||
Luminal A | 0.183(0.085–0.395) | <0.001 | 0.208(0.093–0.466) | <0.001 |
Luminal B | 0.481(0.297–0.779) | 0.003 | 0.421(0.253–0.701) | 0.001 |
HER2+ | 0.568(0.293–1.105) | 0.096 | 0.565(0.287–1.113) | 0.099 |
TNBC | Reference | Reference |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhang, K.; Ping, L.; Ou, X.; Bazhabayi, M.; Xiao, X. A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery. J. Pers. Med. 2021, 11, 413. https://doi.org/10.3390/jpm11050413
Zhang K, Ping L, Ou X, Bazhabayi M, Xiao X. A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery. Journal of Personalized Medicine. 2021; 11(5):413. https://doi.org/10.3390/jpm11050413
Chicago/Turabian StyleZhang, Kaiming, Liqin Ping, Xueqi Ou, Meiheban Bazhabayi, and Xiangsheng Xiao. 2021. "A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery" Journal of Personalized Medicine 11, no. 5: 413. https://doi.org/10.3390/jpm11050413